Applications

1516 – Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for osimertinib

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item

Service or technology in this application

Testing for EGFR gene mutation in patients with locally advanced or metastatic NSCLC.

Type: Investigative

Medical condition this application addresses

Lung cancer is the second leading cause of premature death for all Australians and is the fifth most commonly diagnosed cancer in Australia. NSCLC cancer accounts for over 80% of all lung cancer cases, and is usually diagnosed at an advanced stage when surgical resection may no longer be amenable.

Application documents

Application form

Consultation survey

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 28 - 29 July 2020